Dineth P. Nagahawatta is a cardiovascular scientist and postdoctoral researcher at the University of Alberta. He investigates how neprilysin (NEP) and apelin/APJ signaling drive cardiac remodeling and recovery after myocardial infarction. Using AI-assisted multi-omics and cell-type–specific NEP knockout models, he maps mechanisms and biomarkers of heart-failure progression and evaluates NEP-resistant apelin-17 analogs and small-molecule APJ agonists. His natural-products work spans discovery and translational testing of marine polysaccharides, peptides, and small molecules for inflammation, metabolic dysfunction, and mucosal health. He contributed methods and reviews on fucoidan structure and isolation and led Sargassum projects, including Sargassum coreanum fucoidan that blunts inflammatory signaling and a synbiotic pairing of Sargassum horneri fucoidan with Lactobacillus plantarum to reinforce the intestinal barrier and mitigate IBD-relevant pathways. Related studies on marine polysaccharides and fishery by-product peptides show lipid-lowering, antioxidant, wound-healing, and anti-inflammatory activities—supporting blue-economy pipelines toward functional ingredients and therapeutics. His translational work spans computational docking, preclinical assays, mentoring, peer review, and collaboration. Current interests: NEP–apelin systems biology, drug discovery, and biomarker-guided therapeutics for heart failure.
Dineth P. Nagahawatta is a cardiovascular scientist and postdoctoral researcher at the University of Alberta. He investigates how neprilysin (NEP) and apelin/APJ signaling drive cardiac remodeling and recovery after myocardial infarction. Using AI-assisted multi-omics and cell-type–specific NEP knockout models, he maps mechanisms and biomarkers of heart-failure progression and evaluates NEP-resistant apelin-17 analogs and small-molecule APJ agonists. His natural-products work spans discovery and translational testing of marine polysaccharides, peptides, and small molecules for inflammation, metabolic dysfunction, and mucosal health. He contributed methods and reviews on fucoidan structure and isolation and led Sargassum projects, including Sargassum coreanum fucoidan that blunts inflammatory signaling and a synbiotic pairing of Sargassum horneri fucoidan with Lactobacillus plantarum to reinforce the intestinal barrier and mitigate IBD-relevant pathways. Related studies on marine polysaccharides and fishery by-product peptides show lipid-lowering, antioxidant, wound-healing, and anti-inflammatory activities—supporting blue-economy pipelines toward functional ingredients and therapeutics. His translational work spans computational docking, preclinical assays, mentoring, peer review, and collaboration. Current interests: NEP–apelin systems biology, drug discovery, and biomarker-guided therapeutics for heart failure.